Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 2

Conditions

Shingles

Treatments

Biological: Comparator: placebo (unspecified)

Biological: zoster vaccine live (Oka/Merck)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00109122

V211-007

2005_017

Details and patient eligibility

About

The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).

Full description

The duration of treatment is 12 weeks.

Enrollment

180 patients

Sex

All

Ages

60+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Individuals who are at least 60 years of age with a history of varicella (shingles)
Females must have been postmenopausal.

Exclusion criteria

Subjects who did not previously participate in the main study of this protocol.
Subject had shingles since their 6 month follow-up visit in main phase of study.